CD38 (CD38 molecule)
نویسندگان
چکیده
منابع مشابه
CD38 MOLECULE-A MULTILINEAGE GLYCOPROTEIN AND ITS UNIQUE EXPRESSION ON PLASMA CELLS
A hybridoma clone designated 6G5 has been selected by fusion of mouse myeloma cell line Ag. 8653 with spleen cells from mice immunized with human peripheral blood mononuclear cells (PBMC). The antibody produced by this clone was found to be strongly reactive with four human B-cell lines in the conventional immunological assays. Despite the fact that expression of most B cell-associated mar...
متن کاملCd38/Adp-Ribosyl Cyclase
The multifunctional ADP-ribosyl cyclase, CD38, catalyzes the cyclization of NAD(+) to cyclic ADP-ribose (cADPr). The latter gates Ca(2+) release through microsomal membrane-resident ryanodine receptors (RyRs). We first cloned and sequenced full-length CD38 cDNA from a rabbit osteoclast cDNA library. The predicted amino acid sequence displayed 59, 59, and 50% similarity, respectively, to the mou...
متن کاملCD38 and bone marrow microenvironment.
This review summarizes the events ruled by CD38 shaping the bone marrow environment, recapitulating old and new aspects derived from the body of knowledge on the molecule. The disease models considered were myeloma and chronic lymphocytic leukemia (CLL). CD38 has been analyzed considering its twin function as receptor and enzyme, roles usually not considered in clinics, where it is used as a ro...
متن کاملcd38 molecule-a multilineage glycoprotein and its unique expression on plasma cells
a hybridoma clone designated 6g5 has been selected by fusion of mouse myeloma cell line ag. 8653 with spleen cells from mice immunized with human peripheral blood mononuclear cells (pbmc). the antibody produced by this clone was found to be strongly reactive with four human b-cell lines in the conventional immunological assays. despite the fact that expression of most b cell-associated markers ...
متن کاملTargeting CD38 alleviates tumor-induced immunosuppression
Targeting CD38, a common blood cell membrane receptor highly expressed on many Band T-cell cancers, has achieved significant clinical activity with an acceptable safety profile in multiple myeloma (MM). Specifically, daratumumab (dara) was the first naked CD38 monoclonal antibody (mAb) approved for the treatment of relapsed and refractory MM (RRMM) in 2015. Importantly, it induces high response...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Atlas of Genetics and Cytogenetics in Oncology and Haematology
سال: 2012
ISSN: 1768-3262
DOI: 10.4267/2042/47412